Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stanley Johnsen

Orthopaedic Surgery Phoenix, AZ Medical Doctor

NPI 1932152428 CMS profile 987762

2222 E Highland Ave, Ste 300, Phoenix, AZ 85016

Open in the dashboard

General payments

$1,287

28 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stanley Johnsen of Phoenix, AZ is reported in the CMS Open Payments database as having received $1,287 across 28 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $93 1
2024 General $19 1
2023 General $127 2
2022 General $490 6
2021 General $150 3
2020 General $153 9
2019 General $255 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stanley Johnsen
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Stanley Johnsen were reported at $93. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Stanley Johnsen Orthopaedic Surgery median Middle half National median
2019 $255 $644 $140–$2,844 $163
2020 $153 $312 $75–$1,860 $114
2021 $150 $520 $117–$2,495 $132
2022 $490 $598 $128–$2,731 $149
2023 $127 $461 $128–$2,264 $160
2024 $19 $497 $134–$2,475 $164
2025 $93 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $393 5 payments
  2. Smith+Nephew, Inc. $355 6 payments
  3. ImpactOrtho, Inc. $297 4 payments
  4. Wright Medical Technology, Inc. $82 4 payments
  5. DePuy Synthes Sales Inc. $30 2 payments
  6. Flexion Therapeutics, Inc. $24 1 payment
  7. Goode Surgical Inc $20 1 payment
  8. Vericel Corporation $19 1 payment
  9. Boston Scientific Corporation $19 1 payment
  10. Tactile Systems Technology Inc $18 1 payment
  11. Other $30 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,287 28 payments
Products named General payments · program years 2019–2025
  1. Salto Talaris Total Ankle Prosthesis $148 1 payment
  2. Cadence $148 1 payment
  3. ANCHORAGE $143 1 payment
  4. Bone Anchors with Arthroscopic Delivery System $142 2 payments
  5. AUGMENT INJECTABLE $109 1 payment
  6. INFINITY ADAPTIS $93 1 payment
  7. TWINFIX / DURABRAID $53 2 payments
  8. STAR $37 1 payment
  9. GRAVITY $31 1 payment
  10. BME NITINOL CONTINUOUS COMPRESSION IMPLANTS $30 2 payments
  11. Other $279 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$170,595

Of which drugs: $47,010

Medicare patients

316

Average age 73

Services billed

2,538

208 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 67%
Depression 26%
Ischemic heart disease 23%
Chronic kidney disease 20%
Osteoporosis 20%
Diabetes 16%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 61 384 $35,727
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose J7324 Office 12 91 $8,884
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 94 439 $2,399

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

28 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record